UGRP2 Activators
UGRP2 activators encompass a spectrum of chemical entities that indirectly potentiate the functional activity of UGRP2 through a variety of intracellular signaling cascades. Forskolin, by increasing intracellular cAMP via adenylate cyclase activation, triggers PKA signaling, which in turn can phosphorylate and modify proteins within the same pathways that UGRP2 operates, thus enhancing its activity. Similarly, IBMX and Sildenafil maintain elevated levels of cAMP and cGMP, respectively, by inhibiting their degradation through phosphodiesterases; this results in the sustained activation of PKA and PKG, which could facilitate the upregulation of UGRP2-associated pathways. Additionally, Lithium chloride acts by inhibiting GSK-3, thereby potentially upregulating Wnt signaling, which could lead to the indirect activation of UGRP2. Similarly, the binding of 1,25-Dihydroxyvitamin D3 to its nuclear receptor may alter gene expression patterns, including those of pathways involving UGRP2, resulting in its enhanced functional activity.
Moreover, compounds like Curcumin, which activates NF-κB, and Epigallocatechin gallate (EGCG), a kinase inhibitor, may alleviate negative regulatory controls on pathways involving UGRP2, thereby indirectly increasing its activity. Dibutyryl cAMP acts as a cAMP analog to activate PKA, fortifying the signaling pathways that UGRP2 is a part of. Sodium butyrate, through histone deacetylase inhibition, can indirectly augment gene expression pathways, including those associated with UGRP2. Resveratrol, by activating Sirtuins and influencing AMPK pathways, along with Pioglitazone, which activates PPARγ, modulates numerous signaling pathways that can culminate in the enhanced activity of UGRP2.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels. Elevated cAMP activates PKA, which can phosphorylate various substrates, including those that could be involved in the pathways where UGRP2 is a participant, leading to its enhanced activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP. This increases their levels in the cell, indirectly enhancing PKA and PKG pathways that could increase UGRP2 activity. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid acts on nuclear retinoic acid receptors which modulate gene expression. It can lead to the upregulation of pathways that UGRP2 is involved in, thereby enhancing its activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). This inhibition can lead to the activation of Wnt signaling pathway, which may indirectly enhance the activity of UGRP2 by affecting downstream signaling components. | ||||||
1α,25-Dihydroxyvitamin D3 | 32222-06-3 | sc-202877B sc-202877A sc-202877C sc-202877D sc-202877 | 50 µg 1 mg 5 mg 10 mg 100 µg | $325.00 $632.00 $1428.00 $2450.00 $400.00 | 32 | |
The active form of vitamin D, 1,25-Dihydroxyvitamin D3, binds to the vitamin D receptor and modulates gene expression. This can lead to the activation of signaling pathways that include UGRP2, resulting in its enhanced activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin has been shown to activate transcription factors such as NF-κB, which modulates gene expression. This transcriptional activation can lead to the enhancement of cellular pathways involving UGRP2. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits several protein kinases, potentially reducing negative regulation on pathways where UGRP2 is involved, thus indirectly enhancing UGRP2 activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
db-cAMP is a cell-permeable cAMP analog that activates PKA. PKA activation can lead to the enhancement of pathways in which UGRP2 is a participant, thereby increasing its activity. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate is a histone deacetylase inhibitor that can lead to a more relaxed chromatin structure and thus upregulate gene expression. It could enhance pathways that involve UGRP2. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol activates sirtuins and modulates several signaling pathways, including AMPK. Activation of these pathways can lead to the indirect enhancement of UGRP2 activity. | ||||||